<p>Cwm LLC 在最近提交给证券交易委员会（SEC）的 13F 文件中表示，在第二季度将其在 BioMarin Pharmaceutical Inc.（NASDAQ:BMRN - 免费报告）中的持股比例提高了 46.4%。该机构投资者在本季度额外购买了 27,894 股后，持有该生物技术公司 87,955 股股票。Cwm LLC 在 BioMarin Pharmaceutical 的持股在最近的报告期末价值为 4,835,000 美元。</p>
<ul>
<li>BioMarin 股票能否满足华尔街的高期望？</li>
</ul>
<p>其他机构投资者最近也对该公司的持股进行了调整。V Square Quantitative Management LLC 在第二季度购买了 BioMarin Pharmaceutical 的新股份，价值 25,000 美元。Farther Finance Advisors LLC 在第一季度将其在 BioMarin Pharmaceutical 的持股增加了 95.9%。Farther Finance Advisors LLC 目前持有 431 股该生物技术公司的股票，价值 29,000 美元，此前在上个季度额外购买了 211 股。Rise Advisors LLC 在第一季度购买了 BioMarin Pharmaceutical 的新股份，价值 30,000 美元。Brooklyn Investment Group 在第一季度将其在 BioMarin Pharmaceutical 的持股增加了 2,250.0%。Brooklyn Investment Group 目前持有 564 股该生物技术公司的股票，价值 40,000 美元，此前在上个季度额外购买了 540 股。最后，Banque Transatlantique SA 在第一季度购买了 BioMarin Pharmaceutical 的新股份，价值 71,000 美元。机构投资者持有该公司 98.71% 的股票。</p>
<h2>华尔街分析师的看法</h2>
<p>BMRN 最近成为几份分析师报告的主题。瑞银集团将 BioMarin Pharmaceutical 的目标价格从 113.00 美元上调至 114.00 美元，并在 8 月 5 日的研究报告中给予该股票 “买入” 评级。摩根士丹利将 BioMarin Pharmaceutical 的目标价格从 97.00 美元下调至 96.00 美元，并在 7 月 22 日的报告中对该股票给予 “增持” 评级。古根海姆将 BioMarin Pharmaceutical 的目标价格从 101.00 美元上调至 106.00 美元，并在 8 月 6 日的报告中给予该股票 “买入” 评级。Weiss Ratings 在 10 月 8 日的报告中重新发布了对 BioMarin Pharmaceutical 的 “卖出（d+）” 评级。最后，Zacks Research 在 8 月 13 日的报告中将 BioMarin Pharmaceutical 的评级从 “强力买入” 下调至 “持有”。十三位研究分析师对该股票给予了买入评级，八位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，该股票目前的平均评级为 “适度买入”，平均目标价格为 93.26 美元。</p>
<ul>
<li>3 只超卖股票具有大幅 RSI 反弹潜力</li>
</ul>
<p><strong>查看我们对 BMRN 的最新分析</strong></p>
<h2>BioMarin Pharmaceutical 价格表现</h2>
<p>BMRN 周五开盘价为 52.95 美元。该公司的市值为 101.7 亿美元，市盈率为 15.71，PEG 比率为 0.67，贝塔值为 0.33。该公司的速动比率为 3.60，流动比率为 5.56，债务股本比率为 0.10。该公司的 50 日移动平均价格为 55.74 美元，200 日移动平均价格为 57.67 美元。BioMarin Pharmaceutical Inc. 的 12 个月低点为 51.56 美元，12 个月高点为 73.51 美元。</p>
<h2>BioMarin Pharmaceutical 公司简介</h2>
<p>（免费报告）</p>
<ul>
<li>基因治疗股票会成为市场下一个大赢家吗？</li>
</ul>
<p>BioMarin Pharmaceutical Inc. 开发和商业化针对严重和危及生命的罕见疾病及医疗状况的治疗方案。其商业产品包括 Vimizim，一种用于治疗粘多糖贮积症（MPS）IV 型 A 的酶替代疗法；Naglazyme，一种用于 MPS VI 患者的重组 N-乙酰半乳糖胺 4-硫酸酶；以及 Kuvan，一种用于治疗苯丙酮尿症（PKU）患者的专有合成口服形式 6R-BH4，这是一种遗传代谢疾病。</p>
<h2>了解更多</h2>
<ul>
<li>五只我们更看好的股票，胜过 BioMarin Pharmaceutical</li>
<li>为什么投资 5G？如何投资 5G 股票</li>
<li>Salesforce 期待已久的拐点来了：继续上涨！</li>
<li>3 只值得长期持有的 REITs</li>
<li>Rocket Lab USA 获得华尔街的认可：是时候买入了吗？</li>
<li>什么是成长股及其投资方式</li>
<li>Archer 在战略举措中收购竞争对手的专利宝藏</li>
</ul>
<p><strong>想看看其他对 BMRN 持有的对冲基金吗？</strong> 访问 HoldingsChannel.com 获取 BioMarin Pharmaceutical Inc.（NASDAQ:BMRN - 免费报告）的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Qk1STg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Qk1STg"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 BioMarin Pharmaceutical 吗？</h2>
<p>在考虑 BioMarin Pharmaceutical 之前，你会想听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议现在买入，以便在更广泛的市场注意到之前……而 BioMarin Pharmaceutical 并不在名单上。</p>
<p>虽然 BioMarin Pharmaceutical 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

拜玛林制药

<p>Cwm LLC 在第二季度将其在拜玛林制药（NASDAQ:BMRN）的持股增加了 46.4%，额外购买了 27,894 股，使其总持股达到 87,955 股，价值为 483 万美元。其他机构投资者也调整了他们的持仓。分析师对 BMRN 的评级不一，目标价格范围在 93.26 美元到 114.00 美元之间。该股票开盘价为 52.95 美元，市值为 101.7 亿美元，12 个月的价格区间为 51.56 美元到 73.51 美元。拜玛林专注于罕见疾病的治疗</p>

<p>Cwm LLC lifted its position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 46.4% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 87,955 shares of the biotechnology company's stock after acquiring an additional 27,894 shares during the quarter. Cwm LLC's holdings in BioMarin Pharmaceutical were worth $4,835,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>Cwm LLC 在最近提交给证券交易委员会（SEC）的 13F 文件中表示，在第二季度将其在 BioMarin Pharmaceutical Inc.（NASDAQ:BMRN - 免费报告）中的持股比例提高了 46.4%。该机构投资者在本季度额外购买了 27,894 股后，持有该生物技术公司 87,955 股股票。Cwm LLC 在 BioMarin Pharmaceutical 的持股在最近的报告期末价值为 4,835,000 美元。</p>
</div><ul>
<li>Can BioMarin Stock Live Up to Wall Street’s High Expectations?</li>
</ul>
<div class="lb-trans"><ul>
<li>BioMarin 股票能否满足华尔街的高期望？</li>
</ul>
</div><p>Other institutional investors have also recently made changes to their positions in the company. V Square Quantitative Management LLC bought a new stake in shares of BioMarin Pharmaceutical in the 2nd quarter worth $25,000. Farther Finance Advisors LLC grew its stake in shares of BioMarin Pharmaceutical by 95.9% in the 1st quarter. Farther Finance Advisors LLC now owns 431 shares of the biotechnology company's stock worth $29,000 after acquiring an additional 211 shares in the last quarter. Rise Advisors LLC bought a new stake in shares of BioMarin Pharmaceutical in the 1st quarter worth $30,000. Brooklyn Investment Group grew its stake in shares of BioMarin Pharmaceutical by 2,250.0% in the 1st quarter. Brooklyn Investment Group now owns 564 shares of the biotechnology company's stock worth $40,000 after acquiring an additional 540 shares in the last quarter. Finally, Banque Transatlantique SA bought a new stake in shares of BioMarin Pharmaceutical in the 1st quarter worth $71,000. Institutional investors own 98.71% of the company's stock.</p>
<div class="lb-trans"><p>其他机构投资者最近也对该公司的持股进行了调整。V Square Quantitative Management LLC 在第二季度购买了 BioMarin Pharmaceutical 的新股份，价值 25,000 美元。Farther Finance Advisors LLC 在第一季度将其在 BioMarin Pharmaceutical 的持股增加了 95.9%。Farther Finance Advisors LLC 目前持有 431 股该生物技术公司的股票，价值 29,000 美元，此前在上个季度额外购买了 211 股。Rise Advisors LLC 在第一季度购买了 BioMarin Pharmaceutical 的新股份，价值 30,000 美元。Brooklyn Investment Group 在第一季度将其在 BioMarin Pharmaceutical 的持股增加了 2,250.0%。Brooklyn Investment Group 目前持有 564 股该生物技术公司的股票，价值 40,000 美元，此前在上个季度额外购买了 540 股。最后，Banque Transatlantique SA 在第一季度购买了 BioMarin Pharmaceutical 的新股份，价值 71,000 美元。机构投资者持有该公司 98.71% 的股票。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师的看法</h2>
</div><p>BMRN has been the subject of several recent analyst reports. UBS Group upped their target price on shares of BioMarin Pharmaceutical from $113.00 to $114.00 and gave the stock a &#34;buy&#34; rating in a research note on Tuesday, August 5th. Morgan Stanley cut their price target on shares of BioMarin Pharmaceutical from $97.00 to $96.00 and set an &#34;overweight&#34; rating on the stock in a report on Tuesday, July 22nd. Guggenheim boosted their price target on shares of BioMarin Pharmaceutical from $101.00 to $106.00 and gave the stock a &#34;buy&#34; rating in a report on Wednesday, August 6th. Weiss Ratings reissued a &#34;sell (d+)&#34; rating on shares of BioMarin Pharmaceutical in a report on Wednesday, October 8th. Finally, Zacks Research downgraded shares of BioMarin Pharmaceutical from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a report on Wednesday, August 13th. Thirteen research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of &#34;Moderate Buy&#34; and an average target price of $93.26.</p>
<div class="lb-trans"><p>BMRN 最近成为几份分析师报告的主题。瑞银集团将 BioMarin Pharmaceutical 的目标价格从 113.00 美元上调至 114.00 美元，并在 8 月 5 日的研究报告中给予该股票 “买入” 评级。摩根士丹利将 BioMarin Pharmaceutical 的目标价格从 97.00 美元下调至 96.00 美元，并在 7 月 22 日的报告中对该股票给予 “增持” 评级。古根海姆将 BioMarin Pharmaceutical 的目标价格从 101.00 美元上调至 106.00 美元，并在 8 月 6 日的报告中给予该股票 “买入” 评级。Weiss Ratings 在 10 月 8 日的报告中重新发布了对 BioMarin Pharmaceutical 的 “卖出（d+）” 评级。最后，Zacks Research 在 8 月 13 日的报告中将 BioMarin Pharmaceutical 的评级从 “强力买入” 下调至 “持有”。十三位研究分析师对该股票给予了买入评级，八位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，该股票目前的平均评级为 “适度买入”，平均目标价格为 93.26 美元。</p>
</div><ul>
<li>3 Oversold Stocks with Big RSI Rebound Potential</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只超卖股票具有大幅 RSI 反弹潜力</li>
</ul>
</div><p><strong>Check Out Our Latest Analysis on BMRN</strong></p>
<div class="lb-trans"><p><strong>查看我们对 BMRN 的最新分析</strong></p>
</div><h2>BioMarin Pharmaceutical Price Performance</h2>
<div class="lb-trans"><h2>BioMarin Pharmaceutical 价格表现</h2>
</div><p>BMRN opened at $52.95 on Friday. The company has a market capitalization of $10.17 billion, a price-to-earnings ratio of 15.71, a PEG ratio of 0.67 and a beta of 0.33. The company has a quick ratio of 3.60, a current ratio of 5.56 and a debt-to-equity ratio of 0.10. The firm has a 50-day moving average price of $55.74 and a 200-day moving average price of $57.67. BioMarin Pharmaceutical Inc. has a twelve month low of $51.56 and a twelve month high of $73.51.</p>
<div class="lb-trans"><p>BMRN 周五开盘价为 52.95 美元。该公司的市值为 101.7 亿美元，市盈率为 15.71，PEG 比率为 0.67，贝塔值为 0.33。该公司的速动比率为 3.60，流动比率为 5.56，债务股本比率为 0.10。该公司的 50 日移动平均价格为 55.74 美元，200 日移动平均价格为 57.67 美元。BioMarin Pharmaceutical Inc. 的 12 个月低点为 51.56 美元，12 个月高点为 73.51 美元。</p>
</div><h2>BioMarin Pharmaceutical Company Profile</h2>
<div class="lb-trans"><h2>BioMarin Pharmaceutical 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><ul>
<li>Are Gene Therapy Stocks The Market's Next Big Winners?</li>
</ul>
<div class="lb-trans"><ul>
<li>基因治疗股票会成为市场下一个大赢家吗？</li>
</ul>
</div><p>BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.</p>
<div class="lb-trans"><p>BioMarin Pharmaceutical Inc. 开发和商业化针对严重和危及生命的罕见疾病及医疗状况的治疗方案。其商业产品包括 Vimizim，一种用于治疗粘多糖贮积症（MPS）IV 型 A 的酶替代疗法；Naglazyme，一种用于 MPS VI 患者的重组 N-乙酰半乳糖胺 4-硫酸酶；以及 Kuvan，一种用于治疗苯丙酮尿症（PKU）患者的专有合成口服形式 6R-BH4，这是一种遗传代谢疾病。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than BioMarin Pharmaceutical</li>
<li>Why Invest in 5G? How to Invest in 5G Stocks</li>
<li>Salesforce’s Long-Awaited Inflection is Here: Rally On!</li>
<li>3 REITs to Buy and Hold for the Long Term</li>
<li>Rocket Lab USA Receives Wall Street Validation: Time to Buy?</li>
<li>What Are Growth Stocks and Investing in Them</li>
<li>Archer Buys Rival's Patent Treasure Trove in Strategic Move</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 BioMarin Pharmaceutical</li>
<li>为什么投资 5G？如何投资 5G 股票</li>
<li>Salesforce 期待已久的拐点来了：继续上涨！</li>
<li>3 只值得长期持有的 REITs</li>
<li>Rocket Lab USA 获得华尔街的认可：是时候买入了吗？</li>
<li>什么是成长股及其投资方式</li>
<li>Archer 在战略举措中收购竞争对手的专利宝藏</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding BMRN?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对 BMRN 持有的对冲基金吗？</strong> 访问 HoldingsChannel.com 获取 BioMarin Pharmaceutical Inc.（NASDAQ:BMRN - 免费报告）的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Qk1STg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=BMRN"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in BioMarin Pharmaceutical Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 BioMarin Pharmaceutical 吗？</h2>
</div><p>Before you consider BioMarin Pharmaceutical, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 BioMarin Pharmaceutical 之前，你会想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioMarin Pharmaceutical wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议现在买入，以便在更广泛的市场注意到之前……而 BioMarin Pharmaceutical 并不在名单上。</p>
</div><p>While BioMarin Pharmaceutical currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 BioMarin Pharmaceutical 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Cwm LLC 购买了 27,894 股拜玛林制药公司的股票，股票代码为$BMRN